We are live on
!
Find out more
NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.23B
1-Year Est. Return
81.32%
This Fund
S&P 500
This Quarter
Est. Return
+2.96%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$1.85B
AUM Growth
+$405M
(+28%)
Cap. Flow
+$418M
Cap. Flow
% of AUM
22.56%
Top 10 Holdings %
Top 10 Hldgs %
65.27%
Holding
41
New
6
Increased
10
Reduced
6
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Morningstar Total Stock Market ETF
VTI
|
+$269M |
| 2 |
TEM
Tempus AI
TEM
|
+$125M |
| 3 |
Edgewise Therapeutics
EWTX
|
+$111M |
| 4 |
MRUS
Merus
MRUS
|
+$32.7M |
| 5 |
Celldex Therapeutics
CLDX
|
+$32.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edgewell Personal Care
EPC
|
+$116M |
| 2 |
ASML
ASML
|
+$47.3M |
| 3 |
Insmed
INSM
|
+$20.9M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
+$18.4M |
| 5 |
Inspire Medical Systems
INSP
|
+$14.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 53.05% |
| 2 | Technology | 16.21% |
| 3 | Financials | 9.98% |
| 4 | Communication Services | 2.26% |
| 5 | Consumer Discretionary | 1.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Brookfield Asset Management
BAM
$83.8B
| $23.9M | 1.29% |
627,207
| – | – |
|
27
Rocket Pharmaceuticals
RCKT
$394M
| $23.7M | 1.28% |
1,100,000
+50,000
| +5% | +$1.15M |
|
28
Lexeo Therapeutics
LXEO
$378M
| $23.3M | 1.25% |
1,450,500
-187,798
| -11% | -$2.73M |
|
|
BPMC
29
DELISTED
Blueprint Medicines
BPMC
| $18.9M | 1.02% |
175,000
-183,626
| -51% | -$18.4M |
|
30
Kyverna Therapeutics
KYTX
$484M
| $13.1M | 0.71% |
1,750,000
+1,050,000
| +150% | +$16M |
|
|
MORF
31
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $12.8M | 0.69% |
+375,000
| New | +$11.1M |
|
|
VERV
32
DELISTED
Verve Therapeutics
VERV
| $11.7M | 0.63% |
2,400,000
+400,000
| +20% | +$2.51M |
|
33
Metagenomi Therapeutics
MGX
$46.3M
| $7.34M | 0.4% |
1,800,000
+60,825
| +3% | +$418K |
|
|
IOBT
34
DELISTED
IO Biotech
IOBT
| $5.18M | 0.28% |
4,429,449
-658,809
| -13% | -$921K |
|
35
AbCellera Biologics
ABCL
$2.12B
| $3.34M | 0.18% |
1,126,915
| – | – |
|
36
Marqeta
MQ
$1.66B
| $2.42M | 0.13% |
110,390
| – | – |
|
|
DMRA
37
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.84B
| $1.18M | 0.06% |
99,912
| – | – |
|
38
Spero Therapeutics
SPRO
$73M
| $610K | 0.03% |
468,902
| – | – |
|
|
39
Edgewell Personal Care
EPC
$1.31B
| – | – |
-6,344,430
| Closed | -$116M |
|
|
40
Inspire Medical Systems
INSP
$1.74B
| – | – |
-65,524
| Closed | -$14.1M |
|
41
Treace Medical Concepts
TMCI
$309M
| – | – |
-360,000
| Closed | -$4.7M |
|
Similar funds
MP
FLII
IC
IA
HTHT
BCP
SPC
SC
Novo Holdings A/S's Q2 2024 Portfolio in Review
As of Q2 2024, Novo Holdings A/S held 41 positions worth $1.85B, up 28% from $1.45B the previous quarter. Its ten largest holdings account for 65% of the portfolio.
Novo Holdings A/S deployed $418M of net new capital in Q2 2024, opening 6 new positions and adding to 10 existing holdings. Its largest new stake was Vanguard Morningstar Total Stock Market ETF: 1,038,550 shares worth $278M.
By sector, the portfolio is most concentrated in Healthcare at 53% of assets, up from 45% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was ASML, an estimated $47.3M trimmed.
- Novo Holdings A/S's largest Q2 2024 buy was Vanguard Morningstar Total Stock Market ETF: 1,038,550 shares worth $278M.
- Novo Holdings A/S added most to Kyverna Therapeutics in Q2 2024, an estimated $16M increase.
- Novo Holdings A/S's biggest Q2 2024 reduction was ASML, cutting an estimated $47.3M.
- Novo Holdings A/S fully exited Edgewell Personal Care in Q2 2024, selling an estimated $116M.
- Novo Holdings A/S's ten largest holdings make up 65% of its $1.85B portfolio in Q2 2024.
- Novo Holdings A/S opened 6 new positions and closed 3 in Q2 2024.
- Novo Holdings A/S's portfolio value rose 28% quarter-over-quarter to $1.85B.
Based on Novo Holdings A/S's 13F filing for Q2 2024, filed 14 Aug 2024.